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    INTRODUCTION 
 Peripheral nerve blocks provide an ideal operating condition when used 
optimally. They are said to cause least interference with the vital physiological functions 
of the body with reduced stress response avoiding polypharmacy with an alert and 
cooperative patient when compared to the conventional techniques. Adequately 
administered regional anaesthesia can, not only provide very excellent intraoperative 
pain control but also good post operative analgesia. 
 Regional anaesthesia traces its origin to Dr.Carl Koller, a young viennese 
ophthalmologist, who in 1884 employed a solution of cocaine for topical corneal 
anaesthesia in patients undergoing eye surgeries. Most of the local anaesthetic agents 
developed between 1900 - 1940 were basically aminoester compounds. They lost their 
importance due to shorter duration of action, associated allergic reaction and systemic 
toxicity. This paved the way for the synthesis of newer agents, namely the aminoamide 
compounds. Subsequent newer aminomides have revolutionized the field of regional 
anaesthesia catering to the varying demands of modern surgery. 
 The advent of long acting anaesthetic drugs has made it possible to carry out 
prolonged surgeries in the extremities, especially in orthopaedic, vascular and plastic 
surgeries. The use of specific nerve blocks has additional advantage over spinal and 
epidural anaesthesia in that they are not associated with autonomic blockade. 
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 Bupivacaine has been the widely used local anaesthetic drug for combined 
Femoral nerve block and sciatic nerve block (anterior approach) but Albright in 1979 
published an alarming editorial which associated bupivacaine and etidocaine with cardic 
arrest. The search for a long acting local anaesthetic devoid of cardiotoxicity led to the 
synthesis of Ropivacaine a new amino amide local anaesthetic recently studied in adults. 
Its main characteristics reported to be lesser motor blockade, lesser cardiotoxicity for the 
same duration of analgesia in comparison to bupivacaine. The present study was 
designed to compare ropivacaine and bupivacaine for combined femoral nerve block and 
sciatic nerve block (anterior approach) in patients undergoing lower limb knee and below 
knee orthopaedic procedures. 
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 AIM OF THE STUDY 
The aim of study is 
a. To evaluate the efficacy and safety of 0.5% Bupivacaine with 0.5% Ropivacaine 
for combined femoral and sciatic nerve block (anterior approach) in patients 
undergoing lower limb knee and below knee orthopaedic procedures with regards 
to. 
 i. Onset of sensory and motor blockade 
 
 ii. Duration of sensory analgesia and motor blockade 
 
 iii. hemodynamic changes 
b. To study the associated complications of the procedure. 
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 APPLIED PHYSIOLOGY 
Physiology of Nerve conduction1 
 All peripheral nerves are elongated axons of neurons situated centrally. A typical 
peripheral nerve consists of bundles of motor sensory and other fibres enclosed in the 
outermost covering called epineurium. Inside the epineurium, the perineurium surrounds 
the collection of bundles. Each bundle is surrounded by an endoneurium. Each nerve 
fibre in a bundle is enclosed in a layer of neurilemma or the axonal membrane. 
 Depending on the presence or absence of myelin sheath, it can be a myelinated 
nerve fibre or unmyelinated nerve fibre. 
 The axonal membrane itself is made up of a bimolecular lipid palisade, 
interspersed with large protein molecules. The membrane lipids are largely phospholipid 
composed of a polar head group and a nonpolar hydrocarbon tail. 
 The primary function of the cell membrane is to separate the extracellular from 
the intracellular environment. The major difference between these two environments is 
the ionic concentration; this disequilibrium provides the means for impulse conduction. 
 The most important ions in this respect are sodium and potassium. A membrane 
bound Protein Na+K+ ATPase maintains normal resting equilibrium potential between - 
50 MV to - 90MV by pumping sodium ions out of the cell and potassium ions in to the 
cell. A positive ion gradient form inside the membrane to the outside causes 
electronegativity inside the membrane. 
 
 
11 
 During nerve conduction the following changes occur in the cell membrane. 
In the resting phase 
 There is a potential difference across the membrane, inside is negative, due to a 
higher concentration of sodium ions outside than inside the cell. The cell membrane is 
relatively impermeable to the sodium ions whose gradient is maintained by the sodium 
pump. 
Depolarization phase 
 During excitation, sodium channels in the cell membrane open briefly allowing 
sodium ions to flow into the cell, thereby depolarizing the membrane. 
Neutralisation Phase 
 During this phase, potassium ions pass out of the cell to restore electrical 
neutrality. 
Restoration phase 
 During this phase, sodium ions return to the outside and potassium ions reenter 
the cell. 
 In the myelinated fibre this depolarization occurs only at the nodes of Ranvier 
thus giving rise to saltatory conduction of the nerve impulse thus enabling depolarization 
to spread rapidly. 
 
 The sodium channel is believed to be an integral membrane spanning protein. 
The three dimensional configuration of the protein forms a pore through the neuronal 
membrane. 
 Depolarization of the cell induces a configurational change on the sodium 
channel which causes it to open and allow ion passage. 
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Action of Local anaesthetic 
 The primary action produced is electrical stabilization. The large transient 
increase in permeability to sodium ions necessary for propagation of the impulse is 
prevented. Thus the resting membrane potential is maintained and depolarization in 
response to stimulation is inhibited. 
 Local anaesthetics block sodium conductance probably by dual action on the cell 
membrane. 
1. They act directly on receptors within the sodium channels. They act probably by 
binding to the subunits of the sodium channel protein thereby inhibiting the 
conformational change in the protein during cellular depolarization. 
2. They produce nonspecific membrane expansion. There is an unfolding of 
membrane protein together with a disordering of the lipid component of the cell 
membrane with consequent obstruction of the sodium channels. 
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 APPLIED ANATOMY 
 The lower limb is innervated by two major nerves plexuses 2,3 namely 
1. Lumbar plexus 
2. Lumbosacral plexus 
LUMBAR PLEXUS 
 Supplies Anterior, Medial and Lateral thigh, hip joint, knee joint, and 
anteromedial portion of leg. 
LUMBOSACRAL PLEXUS 
 Supplies posterior part of thigh, knee joint, lateral and posterior portions of leg 
and whole of foot. 
LUMBAR PLEXUS 
 
Formation 
 The Lumbar plexus is derived from the anterior primary rami of 1st, 2nd, 3rd and 
part of 4th lumbar nerve roots. In 50% of the subjects, an additional contribution arises 
from T12. 
 The plexus assembles in the substance of the psoas major muscle. 
 L1 divides in to an upper and lower division. The upper division gives rise to the 
iliohypogastric and ilioinguinal nerves. 
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 The lower division joins a branch from L2 to form the genito femoral nerve. 
 The rest of L2 with L3 and the contribution from L4 divide in to dorsal and 
ventral divisions. 
 Dorsal divisions of L2 and L3 form the lateral cutaneous nerve of thigh and those 
of L2, L3 and L4 form the femoral nerve. 
 The Ventral divisions join to form the obturator nerve. 
LUMBO SACRAL PLEXUS IS FORMED BY: 
 a. Lumbo sacral trunk, ventral rami of L4 and L5. 
 
 b. Ventral rami of S1, S2, S3 and S4. 
 Lumbosacral trunk and the S1, S2 and S3 sacral nerves form the sciatic nerve 
upper band. The sciatic nerve is composed of tibial nerve and common peroneal nerve. 
Usually the sciatic nerve splits into these two components at the apex of popliteal fossa, 
but the division may occur at any level proximally. 
 The lower band more plexiform in arrangement, formed by the junction of S3 and 
portion of S4, is prolonged into the pudendal nerve. 
 Branches include muscular, cutaneous and visceral collateral and terminal, the 
sciatic and pudendal. 
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Cutaneous distribution of lower limb nerves 
 Cutaneous distribution of the lower limb nerves show considerable variation. 
There is a large degree of overlapping between adjacent territories. 
Innervation of deep structures 
 It is generally assumed that muscles and bones are supplied by the same nerves as 
the skin overlying them. 
 Joints have a more complex nerve supply and receive innervation from all the 
nerves supplying structures around them. eg. Hip and knee joints are supplied by 
femoral, sciatic and obturator nerves. Ankle joint is supplied by femoral and sciatic 
nerves. 
Course and Distribution of Nerves of Lower Limb 
 After formation, the branches of the lumbar plexus lie in the fascial plane 
between the psoas major muscle anteriorly and the iliacus muscle posteriorly forming the 
bed. 
 Femoral nerve is the largest nerve of the lumbar plexus and, in brief, supplies 
the muscles and the skin of the anterior compartment of the thigh. The nerve emerges 
from the lateral margin of psoas, passes down wards in the groove between psoas and 
iliacus (to both of which it sends a nerve supply), then enters the thigh beneath the 
inguinal ligament. At the base of the femoral triangle the nerve lies on iliacus, a finger's 
breadth lateral to the femoral artery. Once within the triangle the nerve breaks up in to its 
terminal branches which stem from an anterior and posterior division. 
Anterior division 
Muscular branches to: 
 
 1. Pectineus; 
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 2. Sartorius. 
 
Cutaneous Branches: 
 
 1. intermediate cutaneous nerve of thigh; 
 
 2. medial cutaneous nerve of thigh. 
Posterior Division 
 
 Muscular branches to quadriceps femoris. 
 
 Cutaneous branch - saphenous nerve. 
 Articular branches to: 
  1. hip; 
 
  2. knee. 
 Obturator nerve emerges from the medial border of the psoas at the pelvic brim 
and crosses downward and forward in to the obturator canal. Within the canal it branches 
into anterior and posterior divisions and supplies medial aspect of thigh. 
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 Lateral cutaneous nerve of the thigh emerges form the lateral border of the 
psoas immediately inferior to the ileo-inguinal nerve. Passing over iliacus, the nerve 
enters the thigh by running below the lateral extremity of the inguinal ligament and 
divides into an anterior and a posterior branch. The anterior branch supplies the skin over 
the antero-lateral aspect of the thigh down to the knee. The posterior branch penetrates 
the fascia lata to innervate the skin of the lateral aspect of the leg from the greater 
trochanter to the mid - thigh. 
 Sciatic nerve leaves the posterior pelvic wall through the greater sciatic foramen 
below piriformis and enters the region of the buttock slightly medial to the half way point 
between the ischial tuberosity and the greater trochanter. The nerve then descends 
vertically down the midline of the back of the thigh as for as the apex of the popliteal 
fossa. There it divides into tibial and common peroneal nerves. It supplies the back of the 
thigh, back of the knee joint, anterolateral and posterior aspect of leg and whole of foot 
and ankle joint. 
Branches 
 The branches of the sciatic nerve can be grouped in to the following 
 Muscular : to semitendinosus; semimembranosus; adductor magnus; 
biceps femoris 
 Articular : to the hip joint 
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 Terminal : 
 Tibial (medial popliteal) nerve 
 a. Muscular (to gastrocnemius, plantaris, tibialis posterior, popliteus, 
flexordigitorum longus and flexor hallucis longus); 
 b. Medial calcaneal nerve; 
 c. Medial plantar nerve; 
 d. Lateral plantar nerve; 
 e. Sural nerve. 
 Common peroneal (lateral popliteal) nerve 
 a. Cutaneous nerve of calf; 
 b. Superficial peroneal nerve; 
 c. Deep peroneal nerve. 
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 TECHNIQUES OF FEMORAL AND  
 SCIATIC NERVE BLOCK 
FEMORAL NERVE BLOCK4 
 Blockade of the femoral nerve provides sensory anesthesia of the anterior thigh, 
knee and medial aspect of the calf, ankle and foot. A number of techniques for locating 
the femoral nerve exist, they are 
 i. Nerve stimulator technique 
 
 ii. Seeking paresthesia 
 
 iii. Loss of Resistance technique 
 
 iv. Field block 
The Nerve Stimulator technique 
 In the nerve stimulator technique, the point of needle insertion site is 1.5 cm 
lateral and 1.5 cm distal to the intersection of the inguinal ligament and the femoral 
artery. The teflon - coated nerve stimulator needle is inserted through the skin at 45 
degree angle to the skin and directed cephalad and slightly medially toward the 
umbilicus.A motor evoked response of movement of patella indicates stimulation of 
femoral nerve. After aspiration 10-15ml of Local anaesthetic is injected. 
ii. Seeking paresthesia 
 Eliciting paresthesia provides a definite endpoint for locating the nerve, but 
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requires an awake and responsive patient. Paresthesia elicited during axillary brachial 
plexus block have been associated with neural injury and this has raised concern about 
use of this technique in other peripheral nerve blocks. 
 
iii. Loss of Resistance technique 
 The femoral nerve lies below two facial planes: the fascia lata and the fascia 
iliacus. Simply feeling two successive "pops" as a short bevel regional anaesthesia needle 
passes through these fascial layers indicates placement of the needle in the perineural 
space. 
iv. Field Block 
 When land marks are favourable, blind infiltration of local anaesthetic using 
multiple injections to create a "fan" across the expected route of the femoral nerve is a 
simple and rapid technique. The risk of intravascular injection of a single large volume of 
local anaesthetic is minimized by keeping the needle mobile during injection. 
 The femoral nerve block should be distinguished from the "three-in-one" block, 
the technique of lumbar plexus anaesthesia that achieves anaesthesia of the lateral 
femoral cutaneous and obturator as well as femoral nerves. This technique relies on a 
single injection of large volumes of local anesthetic (30ml or greater) within the neural 
"sheath" with the needle directed cephalad and the subsequent spread of anesthetic 
proximally aided by pressure applied distal to the femoral nerve "sheath" to achieve 
anesthesia of the entire lumbar plexus.  
 The theory behind this block presumes that the local anesthetic will track in the 
fascial plane between the iliacus and the psoas muscles to reach the region of the lumbar 
plexus roots. 
 Surgical anaesthesia of the entire lower extremity can be obtained when the three 
- in - one block is combined with the sciatic block. 
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Sciatic Nerve Block 
 The sciatic nerve can be blocked by various approaches: 
 
i. Classic / Posterior approach - Labat 
ii. Anterior approach - Beck 
iii. Inferior / Lithotomy approach - Raj 
iv. Lateral approach - Ichiyannagi 
v. Parasacral approach - Mansour 
i. Posterior approach4 
 The patient is placed in the lateral decubitus position with the side to be blocked 
uppermost, while the lower leg is kept straight, the ipsilateral hip and knee are flexed and 
a line is drawn between the greater trochanter and the posterior superior iliac spine. At 
the mid point, a 5cm perpendicular line is drawn caudally. These lines are referred to as 
Labatt's lines. A third line is drawn between the greater trochanter and sacral hiatus. 
 The point of injection being where the third line intersects with the second 
perpendicular line. After confirmatory paresthesia (or) motor evoked response 
(dorsiflexion (or) plantarflexion of foot) local anesthetic is injected. 
ii. Anterior approach5 
 The anterior approach to block sciatic nerve is based on the fact that sciatic nerve 
lies just behind lesser trochanter, a bony landmark when approached form anterior aspect 
of thigh. 
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iii. Lithotomy approach6 
 With the patient supine, the ipsilateral leg is flexed 90 degrees at the knee and 90-
120 degrees at the hip. A 22 gauge 3.5 to 5 inch needle is advanced at a right angle to the 
skin at the midpoint of a line connecting the greater trochanter and the ischial tuberosity. 
Local anesthetic solution is injected when paresthesia is encountered. 
iv. Lateral approach7,9 
 The sciatic nerve can also be approached laterally at more than one level as it 
passes through the thigh. Posterior border of the greater trochanter is marked and a line is 
drawn parallel to the femur distally. 
a. High approach 
 Needle entry - at the level of ischial tuberosity. 
b. Mid - thigh approach 
 Needle entry - half way between knee and greater trochanter. 
c. Low approach 
 Needle entry - in the gap between vastus lateralis and biceps femoris at 8cm 
proximal to the popliteal fossa crease. 
 Local anaesthetic solution is injected when motor evoked response of 
dorsiflexion or plantar flexion of foot is elicited. 
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v. Parasacral approach8 
 The parasacral approach is uniquely different from traditional sciatic nerve 
blocks as it blocks the root elements of sacral plexus. Patient was placed in sims position 
with operative site non dependent. Operative extremity was flexed 45 at hip and 90 at 
knee joint. Posterior superior iliac spine (PSIS) and Ischial tuberosity (IT) were 
identified. A line was drawn between PSIS and IT. 6m distal from PSIS along the same 
line is the point of needle entry. After motor evoked response local anaesthetic is 
injected. 
COMPLICATIONS OF LOWER LIMB NERVE BLOCKS 
 1. Infection 
 2. Hematoma 
 3. Vascular puncture 
 4. Local anesthetic toxicity 
 5. Nerve injury 
CONTRAINDICATIONS OF LOWER LIMB NERVE BLOCKS 
 
Absolute 
  Infection (or) hematoma in the vicinity of the puncture site 
  Lesion of the nerves to be stimulated distal to the puncture site 
  Patient refusal 
Relative 
  Neurological defecit of the leg to be anaesthetised. 
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 ELICITED MOTOR RESPONSES FOR LOWER LIMB BLOCK9 
 
Technique Motor Response Muscle Innervated Nerve Accept Comment 
Lumbar Plexus 
(Posterior) 
Knee flexion Hamstrings L4 root to the 
sacral plexus 
x Too medial / too 
caudad 
 Hip flexion Psoas major Direct muscle 
stimulation 
x Too deep 
 Patellar twitch Quadriceps femoris Femoral nerve 
L3/4 components 
__  
Femoral Nerve Block 
(Anterior approach) 
Anterior thigh Sartorius Nerve to sartorius x Too superficial 
 Patellar twitch Quadriceps femoris Femoral Nerve __  
Sciatic Nerve Block 
(all approaches) 
Foot plantar-flexion/ 
inversion 
Gastrocnemius and all 
muscles in posterior 
compartment of lower leg. 
Tibial nerve __  
 Foot dorsi - flexion and 
eversion 
Peroneal muscles Common 
peroneal (fibular) 
nerve 
__  
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 PHARMACOLOGY OF LOCAL ANAESTHETICS10,11 
 A local anaesthetic drug is one which reversibly blocks nerve conduction beyond 
the point of application, when applied locally in the appropriate concentrations. 
 Commonly used local anaesthetics are either aminoacyl or aminoalkyl amides. 
The amine group confers on the molecule, the property of a weakbase, which can 
combine with an acid to form a water soluble salt. This salt ionizes in solution and is 
usually stable. The base forms of the amide local anaesthetics are virtually insoluble in 
water. Hence local anesthetics are prepared commercially as hydrochloride salts and 
these solution have a highly acidic pH. 
MECHANISM OF ACTION OF LOCAL ANAESTHETICS 
 When solution of local anaesthetics are deposited near the nerve, diffusion of 
drug molecules away from the locus is a function of: 
 1. Tissue binding 
 2. Removal from the circulation 
 3. Local hydrolysis of aminoester anaesthetics 
 Only the remaining molecules penetrate the nerve sheath. 
 Local anaesthetic molecules permeate the nerve axon membrane and equilibrate 
there and in the axoplasm. The spread and extent of these processes depend on a 
particular drug's pKa and the lipid solubility of the base and cation species. Binding of 
local anaesthetic to the site of voltage gated Na+ channels prevents the opening of 
channels by inhibiting conformational changes that normally produce channel activation. 
Rates of onset and recovery from blockade are governed by the relatively slow diffusion 
of local anesthetic molecules into and out of the nerve and not by the much faster binding 
and dissociation to ion channels. 
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PHARMACODYNAMICS OF LOCAL ANAESTHETICS 
 Conduction blockade of a local anaesthetic is dependent on three physiochemical 
properties namely. 
 1. Lipid solubility which determines the onset of tissue penetration and 
potency of the drug. 
 2. Protein binding characteristics which determine the duration of action. 
 3. pKa which determines the onset time of a local anaesthetic pKa of a drug 
is defined as the pH at which the drug exists 50% in the ionized form and 
50% in the nonionized form. The uncharged basic form of local 
anaesthetic is primarily responsible for diffusion across the nerve shealth, 
while the cationic form of the drug is responsible for the nerve blocking 
effect. 
 In general at a tissue pH of 7.4 the proportion of local anaesthetic which exists in 
the unionized form is inversely proportional to its pKa. Thus a drug like lignocaine with 
pKa of 7.74 will be 65% ionized and 35% unionized at tissue pH. On the other hand 
amethocaine which has a pKa of 8.6 will be 95% ionized and 5% unionized and thereby 
the onset of action is delayed. 
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PHARMACOKINETICS OF LOCAL ANAESTHETICS 
 Concentration of local anaesthetic in blood is determined by: 
1. Rate of absorption from the site of injection. 
2. Rate of distribution. 
3. Rate of metabolism and excretion of the agent. 
 Systemic absorption of a local anaesthetic agent is determined by the site of the 
injection, the dosage, the addition of vasoconstrictors and the pharmacological 
characteristics of the agent. Eg. Lipid solubility, vasoactive properties etc. 
 Local anaesthetic agents are distributed throughout total body water. The 
distribution can be described by a 3 compartment model. 
1. Alpha phase relates to uptake by rapidly equilibrating tissues eg. Brain and 
heart. 
2. Beta Phase refers to uptake by tissues with lower perfusion e.g. Muscles and 
bones. 
3. Gamma Phase is determined by the rate of metabolism and excretion of the 
agent. 
Local Anaesthetic Toxicity 
 Systemic toxicity is primarily a function of plasma levels and can be altered by 
multiple drug's and patient factors. Toxicity usually follows intravenous injection of a 
large dose of local anesthetic. 
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 The commonly used local anaesthetics are racemic mixtures of stereoisomer. 
Studies with bupivacaine have shown that the `R' isomer has significantly more 
cardiotoxicity with no increase in local anaesthetic potency and therefore its presence 
accounts for a significant element of the cardiovascular toxicity of bupivacaine. 
Ropivacaine, an analogue of bupivacaine is the optically pure S- isomer and 
demonstrates equivalent anaesthetic potency to bupivacaine with significantly less 
cardiotoxicity. 
 Local anaesthetic systemic toxicity is primarily manifested as a derangement of 
the central nervous system and the cardiovascular system. 
CENTRAL NERVOUS SYSTEM 
 Local anaesthetics can cause both excitation and depression of the CNS 
depending on the plasma level. Depression of inhibitory pathways in the cerebral cortex 
occurs at lower plasma concentrations than those required for generalized CNS 
depression. This allows excitatory neurons to function in an unopposed fashion initially. 
 Symptoms are lightheadedness, dizziness, oro-facial numbness, visual and 
auditory disturbances, disorientation and drowsiness. 
 Signs include shivering, muscular twitching and tremors initially involving 
muscles of the face and distal parts of the extremities. These may progress to generalized 
convulsions of a tonic - clonic nature. 
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Comparative Central Nervous System Effects 
 In a study with unpremeditated, unanesthetized dogs, there was no difference in 
the CNS toxicity of ropivacaine and bupivacaine. The seizures were shorter with 
ropivacaine as compared to bupivacaine, suggesting that the clearance of ropivacaine was 
closer to that of bypivacaine. 
Prophylaxis and Treatment of CNS toxicity 
  Avoid administration of inappropriately large doses. 
  Fractionation of the required bolus dose 
  Early control of seizures and ventilation Significantly reduces overall 
mortality. 
Cardiovascular system toxicity 
 Systemic absorption of local anesthetic agents can except direct effects on both 
cardiac muscle and vascular smooth muscle resulting in a broad range of effects. 
1. Initial CVS stimulation stage 
 Hypertension 
 Tachycardia 
2. Primary CVS depressant stage 
 Negative Inotropism 
 Decreased cardiac output 
 Mild - moderate hypotension 
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3. Secondary CVS depressant stage 
 Marked decrease in cardiac output 
 Peripheral vasodilatation 
 Profound hypotension 
4. Terminal CVS depressant stage 
 Sinus bradycardia 
 Intracardiac conduction defects 
 Ventricular arrhythmias 
 Cardiac arrest 
 The aetiology of these bupivacaine induced arrhythmias is related to the 
prolonged inhibition of sodium conductance in the cardiac membrane. It also blocks slow 
calcium channels and potassium channels. Bupivacaine is 16 times as potent as 
lignocaine in inducing ventricular arrhythmias. Bupivacaine has been characterized as a 
"fast-in, slow -out" agent. 
Cardiac Resuscitation 
 Isoprenaline 1-2 μg/min is effective in treating the bradycardia and reversing the 
depression of atrial and ventricular conduction caused by bupivacaine. Amrinone a 
phosphodiesterase inhibitor also appears to increase survival in animals treated with toxic 
doses of bupivacaine. 
 Cardiopulmonary resuscitation following collapse can be extremely difficult. 
Hypoxia and acidosis develop very quickly. Massive doses of cardiac stimulants and 
prolonged efforts at mechanical chest compression may be necessary. 
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 PHARMACOLOGY OF BUPIVACAINE10,11 
 Bupivacaine is an aminoacyl amide synthetic local analgesic, which has been 
synthesized at AB Bofors by AF EKENSTAM et al. (1957). Clinically used by Telivuoin 
in 1963 it is produced for clinical use as a racemic mixture of the enantiomer containing 
equal proportions of the `S' and `R' forms. 
 
PHYSIOCHEMICAL PROPERTIES 
 Bupivacaine has a butyl group on the piperidine nitrogen atom of the molecule. It 
is a long acting local anaesthetic drug with high anaesthetic potency. It is more lipid 
soluble, highly protein bound and has greater intrinsic potency. It is 3-4 times as potent 
as lignocaine. It crosses the placenta and the blood brain barrier. 
1. Molecular weight base  - 288 
2. pKa    - 8.1 
3. Partition coefficient  - 346 
4. Mean uptake ratio  - 3.3 
5. Protein Binding  - 96% 
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PHARMACOLOGICAL PROPERTIES 
Onset    Moderate 
Relative Potency  8 
Duration   Long acting 
MECHANISM OF ACTION 
 Bupivacaine produces electrical stimulation of the membranae by dual action on 
sodium conductance. 
 1. Acts directly on the receptors within the sodium channels. 
 2. Produces non - specific membrane expansion 
PHARMACOLOGICAL EFFECTS 
 a. Local  : Nerve Blockade 
 b. Regional : Pain, temperature, touch, motor power and 
vasomotor tone in the region supplied by the 
nerves are blocked. 
 c. Systemic : Effects occurring as a result of systemic 
absorption or intravenous administration. 
 On the cardiovascular system, the effect of bupivacaine is dose related. It 
depresses the automaticity of the heart and myocardial contractility. Depending on the 
membrane potential and the rate of stimulation, bupivacaine depresses Vmax 
considerably more than lignocaine and results in slowed conductance of the cardiac 
action potential which is manifested by prolongation of the RR and QRS intervals of the 
electrocardiogram. This results in rentrant phenomena and ventricular arrhythmias. The 
sodium channels are blocked in a "fast-in, slow out" manner which causes difficulty in 
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resuscitation when ventricular fibrillation has occurred. The cardiotoxicity of 
bupivacaine results from high lipid solubility and the R-enantiomer is more toxic than S-
enantiomer. Bupivacaine produced more severe arrhythmias than ropivacine in the 
development of ECG disturbance and severe myocardial depression was more rapid with 
bupivacaine than ropivacaine. 
PHARMACOKINETICS 
Volume of distribution at 
Steady state (Vss)   - 73 litres 
Terminal elimination  life - 210 minutes 
Clearance    - 0.58 litres/ min 
Plasma protein binding - 96% 
Metabolism    - Liver by N-dealkylation to 
pipecolyloxlidine 
Excretion    - 5% kidney as unchanged drug and rest as 
metabolites. 
Preparations available 
0.125% 
0.25% 
0.5% 
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Contraindications 
1. Hypersensitivity  : Very rare; but has been recorded 
2. Intravenous regional anesthesia 
3. High concentrations in obstetric patients 
Mode of Use 
 Minor nerve block  : 0.25 - 0.5% 
 Major nerve block  : 0.25 - 0.5% 
 Epidural (analgesia) : 0.25 - 0.5% 
 Epidural (for surgery) : 0.5 - 0.75% 
 Spinal   : 0.5% 
the maximum safe dose depends on: 
 1. Route of administration 
 2. Addition of vasoconstrictor 
 Recommended dose : 2-3mg/kg 
      3-4 mg/kg with adrenaline. 
 The addition of epinephrine will decrease plasma levels of bupivacaine in lower 
extremity blocks.12 
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 PHARMACOLOGY OF ROPIVACAINE10,11 
 Ropivacaine is a new aminoamide local anaesthetic. It is the monohydrate of the 
hydrochloride salt of  1 - propyl - 2', 6' - pipecoloxylidide and is prepared as a pure S-
enantiomer. 
 
 
 
 Pipecoloxylidides were first synthesized in 1957 and have been in clinical use for 
more than 30 years. Ropivacaine has a propyl group on the piperidine nitrogen atom of 
the molecule. 
 The pipecoloxylidides are chiral drugs because the molecules possess as 
asymmetric carbon atom and they  may have left - (Sinister) or a right (rectus) handed 
configuration. 
 Ropivacaine is produced as the single "S" enantiomer. It has an enantiomeric 
purity of 99.5% and is prepared by alkylation of `S' enantiomer of dibenzoyl - L  - tartaric 
acid. 
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PHYSIOCHEMICAL PROPERTIES 
 The physiochemical properties of Ropivacaine are as follows 
 1. Molecular weight (base)    : 274 
 2. pKa       : 8.1 
 3. Partition coefficient (N Heptane/ buffer) : 2.9 
 4. Mean uptake ratio (rat sciatic nerve)  : 1.8 
 5. Protein binding %     : 94 
PHARMACOLOGIC PROPERTIES 
 The relative lipid solubility of ropivacaine as measured by partitioning studies 
between N-heptane buffer and relative mean uptake into rat sciatic nerves, shows 
ropivacaine to be intermediate between bupivacaine and lignocaine. Plasma - protein 
binding is marginally less than that of bupivacaine but the pKa is identical. 
 Onset  : Moderate 
 Relative Potency : 6 
 Duration  : Long acting 
MECHANICSM OF ACTION 
 Ropivacaine blocks the generation and the conduction of nerve impulses, 
presumably by increasing the threshold for electrical excitation in the nerve, by slowing 
the propagation of the nerve impulse, and by reducing the rate of rise of action potential. 
The progression of anaesthesia is related to the diameter, myelination and conduction 
velocity of affected nerve fibers. 
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The order of loss of nerve function clinically is as follows: 
 1. Pain   2. Temperature 3. Touch 
 4. Proprioception 5. Skeletal muscle tone 
PHARMACOKINETICS 
 In human volunteers the pharmacokinetics characteristics of ropivacaine have 
bene determined after intravenous infusion. 
 Clearance    - 0.82  0.16 litres/min 
 Plasma protein binding - 94  1% 
 Volume of distribution at  - 59  7 litres 
 Steady state (Vss) 
 Terminal elimination  life - 111  62 min 
 Metabolism    - Liver by aromatic hydroxylation 
by cytochrome P4501A to 3 - 
hydroxy ropivacaine 
 Excretion    - 86% via the kidney, 1% 
unchanged drug, rest as 
metabolites. 
 The higher clearance of ropivacaine over bupivacaine is advantageous in terms of 
lesser systemic toxicity. 
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ABSORPTION 
 The systemic concentration of ropivacaine is dependent on the total dose and 
concentration of drug administered, the route of administration, the patient's 
hemodynamic condition and the vascularity of the administration site. From the epidural 
space, ropivacaine shows complete and biphasic absorption. The half - lives of the two 
phases are 14  7 minutes and 4.20.9 hrs (means S.D) respectively. The slow absorption is 
the rate limiting factor in the elimination of ropivacaine which is why the terminal half 
life is longer after epidural than after intravenous administration. Ropivacaine shows 
dose proportionality up to the highest intravenous dose studies, 80 mg corresponding to a 
mean 1.9  0.3 μg/ml. 
DISTRIBUTION 
 After intravascular infusion, ropivacaine has a steady state volume of distribution 
of 59  7 litres. Ropivacaine is 94% protein bound, mainly to α1 acid glycoprotein. An 
increase in total plasma concentration during continuous epidural infusion has been 
observed, related to postoperative increase of α1 acid glycoprotein variations in unbound, 
i.e. pharmacologically active concentrations have been less than in total plasma 
concentrations. Ropivacaine readily crosses the placenta and rapidly equilibrium is 
reached in regard to unbound concentration. 
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METABOLISM 
 Ropivacaine is extensively metabolised in the liver, predominantly by aromatic 
hydroxylation mediated by cytochrome P4501A to 3- hydroxy ropivacaine. 
Approximately 37% of the total dose is excreted in the urine as both free and conjugated 
3-hydroxy ropivacaine. Low concentrations of 3- hydroxy ropivacaine have been found 
in the plasma. Urinary excretion of the 4-hydroxy and both the 3-hydroxy and 4-hydroxy 
N-dealkylated metabolites accounts for less than 3% of the dose. An additional 
metabolite, 2 - hydroxy methyl ropivacaine has been identified but not quantified in the 
urine. Both 3-hydroxy and 4-hydroxy ropivacaine have a local anaesthetic activity in 
animal models less than that of ropivacaine. There is no evidence of in vivo racemization 
in urine of S(-) ropivacaine to R(+) ropivacaine. 
ELIMINATION 
 The kidney is the main excretory organ for most local anaesthetic metabolites. In 
total, 86% of the ropivacaine dose is excreted in the urine after intravenous 
administration of which only 1% relates to unchanged drug. Ropivacaine has a mean 
total plasma clearance of 387  107 ml/min. The mean  SD terminal half life is 1.8  0.7h 
after intravascular administration and 4.2  1.0h after epidural administration. 
 
 
 
34 
PHARMACODYNAMICS 
Primary Pharmacodynamics (Animal Studies) 
 These studies showed that ropivacaine at low concentration produced a profound 
and rapid block of both Aδ and C fibers and was more potent than similar low 
concentrations of bupivacaine. 
 At higher concentrations, ropivacaine and bupivacaine had similar blocking 
properties. Aδ fibre blocking was 16% greater with bupivacaine and the degree of C fibre 
block was similar with both the drugs. 
 Ropivacaine is a potent producer of frequency (or use) dependent blocks (i.e) a 
block which occurs only when the fibre is stimulated Ropivacaine blocked `C' fibers 
faster than A fibers. 
 Low pKa and high lipid solubility of a local anesthetic drug favoured A over C 
fibre block. The lower lipid solubility of ropivacaine over bupivacaine is presumed to 
retard penetration into myelin sheath. 
 This geater degree of differential block with ropivacaine at low concentration and 
the property of producing frequency dependent block were considered to offer clinical 
advantages in providing analgesia with minimal motor block. 
Secondary Pharmacodynamics 
 Addition of epinephrine to ropivacaine has no limiting effect on the systemic 
absorption of ropivacaine13. Systemic absorption can produce effects on the central 
nervous and cardiovascular systems. At blood concentrations achieved with therapeutic 
doses, changes in cardiac conduction, excitability, refractoriness, contractility and 
peripheral vascular resistance are minimal. However, toxic blood concentrations depress 
cardiac conduction and excitability, which may lead to atrioventricular block, ventricular 
arrhythmias and to cardiac arrest. In addition, myocardial contractility is depressed and 
peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood 
 
 
 
35 
pressure. 
 Ropivacaine can produce central nervous system stimulation, depression or both. 
Apparent central stimulation is usually manifested as restlessness, tremors, shivering, 
progressing to convulsions, followed by depression and coma, progressing to respiratory 
arrest. However, ropivacaine has a primary depressant effect on the medulla and on 
higher centers. The depressed stage may occur without a prior excited stage. 
IN-VIVO STUDIES 
 The effect of local anaesthetics on the electrophysiology of the heart has been 
defined. The maximal rate of increase in the cardiac action potential (Vmax) is largely 
dependent on sodium ion influx via the sodium channels. All local anaesthetics are 
known to depress Vmax in a dose dependent manner. 
 Ropivacaine is intermediate between lignocaine and bupivacaine in decreasing 
Vmax. Exogenous progesterone has no additional effect on depression of Vmax. 
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 Ropivacaine administered by the intravenous route was found to be less toxic 
than bupivacaine Mild CNS symptoms and minor cardiovascular toxicity occur at lower 
dosage and lower plasma concentrations with bupivacaine compared with ropivacaine. 
 Two human volunteer studies of lumbar extradural block using 0.1%, 0.2%, or 
0.3% of Ropivacaine 10ml or 0.25% Bupivacaine 10ml followed by continuous infusion 
of 10ml/hr of the same drug for 21 hours showed a similar spread of sensory block, 
reduced intensity of motor block and quick recovery which offers a distinct advantage in 
the clinical setting during extradural analgesia for labour or post-operative pain. 
ADVERSE REACTIONS 
 A major cause of adverse reactions may due to excessive plasma levels which 
may be due to overdosage, unintentional intravascular injection or slow metabolic 
degradation. Most adverse events reported were mild and transient. 
Central nervous system reactions 
 These are characterized by excitation and/or depression. Restlessness, anxiety, 
dizziness, tinnitus, blurred vision or tremors may occur, possibly proceeding to 
convulsions. However, excitement may be transient or absent with depression being the 
first manifestation. This may quickly be followed by drowsiness, unconsciousness and 
respiratory arrest. Other effects may be nausea, vomiting, chills and constriction of 
pupils. 
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Cardiovascular System Reactions 
 High doses of accidental intravascular injection may lead to high plasma levels 
and related depression of myocardium, decreased cardiac output, heart block, 
hypertension, bradycardia ventricular arrhythmias including ventricular tachycardia and 
ventricular fibrillation and possibly cardiac arrest. 
Preparations available 
 
 0.2% 
 0.5% 
 0.75% 
 1% 
Uses 
 1. Infiltration Anaesthesia 
 2. Peripheral Nerve Blocks 
 3. Brachial Plexus Block 
 4. Lumbar Extradural Block 
   Especially labour analgesia 
 5. Subarachnoid Block 
 6. Caudal Block 
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 REVIEW OF LITERATURE 
 Regional anaesthesia involves the use of a local anaesthetic strategically placed 
along the nerve course to produce surgical anaesthesia. Bupivacaine is the most widely 
used local anaesthetic drug. How ever one major disadvantage of bupivacaine is its 
cardiac toxicity. This was recognised after numerous reports of cardiac arrest that were 
followed by difficult and often unsuccessful resuscitation subsequent to unintended 
intravascular injection of large amount of drug. 
 Ropivacaine is the S-enanitomer of a new amide local anaesthetic which has 
many of the desirable local anaesthetic effects seen with bupivacaine. Several areas of 
superiority for ropivacaine compared with bupivacaine have been identified, including a 
lower potential to produce motor blockade and a higher dose requirement to produce 
cardiotoxicity. 
 Winnie AP, Ramamurthy S. and Durrani Z (1973)14 described the inguinal 
perivascular technique of lumbar plexus anaesthesia. They documented the blockade of 
femoral nerve, lateral cutaneous nerve of thigh and obturator nerve with a single injection 
and this came to be known as the 3-in-1 block. 
 Anker - Moller E, Dahl JB et al., (1990)15 performed inguinal perivascular 
block (3-in-1 block). The three main nerves from the lumbar plexus may be blocked by 
injection of local anaesthetic into the fascial envelope of the femoral nerve (3-in-1 block). 
The femoral nerve may be localised by obtaining paresthesia, by employing a nerve 
stimulator or by the loss of resistance technique. They preferred the use of a nerve 
stimulator. The "3-in-1 block" may be employed for immediate pain relief and for 
treatment of postoperative pain from fractures of the hip, femur and knee. 
 Sansone V.De Ponti A, et al., (1999)16 performed combined sciatic and femoral 
nerve block for knee arthroscopy. Selective block of the femoral and sciatic nerve was 
performed on 601 patients undergoing knee arthroscopy. The results were good in 87%, 
adequate in 12% and poor in 1%. The whole knee surface was covered by the nerve 
blockade. The duration of anaesthesia was 152  21 min and that of analgesia, was 336   
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18 min. No correlation was observed between the effectiveness of the anaesthesia and 
type of surgery performed. They concluded that the technique described thus proved 
adequate for knee arthroscopic surgery, reproducibility was excellent, costs and hospital 
stays were reduced with respect to general anaesthesia, and surgeon and patient 
satisfaction was high. 
 Manani G, Angel A et al., (1982)17 compared sciatic nerve block by the anterior 
and posterior approach for operations on the lower extremity. The results of the analgesia 
block of the lower extremity by means of an anterior (150 patients) or a posterior (114 
patients) approach to the sciatic nerve, along with "3-in-1 block" were compared. The 
sciatic nerve block by anterior approach granted a more prolonged analgesia. They 
concluded that this technique was suitable for trauma patients immobilized in the supine 
position, for patients with skeletal traction on zupinger frame, both for surgery and for 
closed reduction of lower extremity fractures. 
 Vloka JD, Hadzic a et al., (2001)18 studied the influence of leg rotation for the 
success of anterior approach to scientic nerve block. In the anterior approach for sciatic 
nerve block, the femur often obstructs the passage of the needle towards the sciatic nerve. 
They carried out the study by using human cadaver model and assessed how internal and 
external rotation of the leg influences the accessibility of sciatic nerve with the anterior 
approach. They concluded that internal rotation of the leg may significantly facilitate the 
needle insertion in the anterior approach to sciatic block compared to external rotation 
and neutral position. 
 McNicol LR et al., (1985)19 performed sciatic nerve block by anterior approach 
for post operative pain relief in children. The technique of block differed slightly from 
that used in adult practice, in that great reliance was placed on the loss of resistance felt 
as the needle point passed through the thigh muscles into the sciatic neurovascular 
compartment. There were no immediate late complications associated with this block in 
any of the patients. It is concluded that the block is easy to perform and can produce 
reliable post operative analgesia for foot and ankle procedures in pediatric practice. 
 Luber MJ, Greengrass R et al., (2001)20 studied the patient satisfaction and 
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effectiveness of Lumbar plexus and sciatic nerve block for total knee arthroplasty. 
Patients for study were a continuous group of 87 patients over a 1 year period. All 
patients were contacted by phone for a satisfaction survey. A subset of patients studied 
for post operative analgesia revealed an average time of 13 hrs before the first request for 
supplemental narcotics. They observed that there was a 92% overall satisfaction rate with 
the anaesthesia provided by Lumbar plexus block. They concluded that Lumbar plexus 
and sciatic nerve analgesia, leading to increased patient comfort and satisfaction. 
 Allen JG, Denny NM et al., (1998)21 carried out a study comparing spinal 
anaesthesia and combined sciatic femoral 3-in-1 block for post operative analgesia 
following total knee arthroplasty. 39 patients studied were randomly assigned to receive 
either subarachnoid block (n=19) or sciatic femoral block (n=20) visual analogue pain 
scores and morphine requirements were recorded for 48 hrs following surgery. They 
observed that comparison with spinal anaesthesia, sciatic femoral block resulted in 
superior analgesia and reduced morphine consumption for first 24 hrs following total 
knee arthroplasty. 
 Jankowski CJ, Girsch et al., (1997)22 compared femoral 3-in-1 block in with 
spinal, epidural and general anaesthesia in out patients undergoing knee arthroscopy. 
They found that 3-in-1 block patients had shortened hospital stay, decreased nausea and 
vomiting and improved post operative analgesia. 
 Marhofer P, Schrogendorferk et al., (1998)23 studied combined sciatic nerve, 
3-in-1 block in high risk patients. They reported on a case of combined 3-in-1 block and 
sciatic nerve block for amputation of lower limb in an ASA IV-V patient six days after 
intraoperative cardiopulmonary resuscitation following induction of general anaesthesia. 
Regional anaesthesia was conducted with a combination of` sciatic nerve block via 
posterior approach and 3-in-1 block facilitated by ultrasonographic guidance. For each of 
the blocks, they used 20ml of 1% mepivacaine. Sensory blockade was sufficient and 
patients hemodynamic and respiratory status remained stable. They concluded that this 
techniques is a safe method for surgery in lower limb particularly in hemodynamically 
unstable patients. 
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 Pham - Dang C, Beaumonts et al., (2000)24 reported a case of acute toxic 
reaction following lumbar plexus block with bupivacaine. The patient experienced 
ventricular dysrhythmia and seizures five minutes after the injection of 30 ml of 0.5% 
bupivacaine with 1 in 200,000 adrenaline following lumbar plexus block. The patient 
who underwent his hip arthroplasty was still anaesthetized and under controlled 
ventilation at the time of bupivacaine administration. Aspiration test performed before 
injection was negative. Normal cardiac activity and stable hemodynamic conditions were 
restored after 1 hour of resuscitation including 15 electric shocks and administration of 
40mg epinephrine and clonidine 300 μg. 
 Mc Clure JH (1996)25 in his review article on ropivacaine has stated a 
favourable cardiotoxic profile of ropivacacine compared with bupivacaine, confirmed in 
pigs. An electro physiological toxicity ratio, based on the inverse of amount of local 
anaesthetic agent required as 1.6:7:15 for lignocaine, ropivacaine and bupivacaine. 
Bupivacaine has also been found to be more cardiotoxic than equivalent doses of 
lignocaine or ropivacaine in isolated perfused rabbit heart (Lagendorff preparation). 
Bupivacaine produced more severe arrhythmias than those observed with ropivacaine, 
lignocaine was devoid of arhythmogenicity. The development of ECG disturbances and 
severe myocardial depression was more rapid with bupivacaine than ropivacaine. 
 Greengrass RA, Klein SM et al., (1998)26 compared ropivacaine and 
bupivacaine for combined 3-in-1, sciatic nerve block for knee arthroplasty. Patients were 
assigned (20 per group) to receive 3-in-1 block with 30ml of local anaesthetic and sciatic 
nerve block using 15 ml of local anaesthetic with either 0.5% bupivacaine or 0.5% 
ropivacaine. All solutions contained fresh epinephrine 1:400,000. Every one minute after 
local anaesthetic injection, patients were assessed to determine loss of motor function and 
loss of pin prick sensation in the L5-S1 dermatomes. Time to request first analgesia was 
documented from PCA pump. This time was used as evidence of block regression. The 
mean onset time of both motor and sensory blockade was between 14 and 18 min in both 
groups. Duration of sensory blockade was slightly prolonged in bupivacaine (15.3 hours) 
than in ropivacaine group (13.2 hours). They concluded that bupivacaine 0.5% and 
ropivacaine  0.5% have a similar onset of motor and sensory blockade when used for 
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combined 3-in-1 block and sciatic nerve block. Analgesic duration from 0.5% 
bupivacaine was slightly prolonged compared with an equal volume of ropivacaine 0.5%. 
 Marhofer P et al., (2000)27 evaluated the sensory onset time and quality of 
sensory block of ropivaccaine for 3-in-1 block. The sensory onset time and the quality of 
sensory block was assessed by pinprick test in the central sensory region of each of the 3 
nerves. They found no significant differences in sensory onset time between ropivacaine 
group and bupivacaine group. They concluded that the sensory onset time and quality of 
sensory block during 3-in-1 block performed with ropivacaine are comparable to those 
with bupivacaine. 
 Beccaria P, Fanelli G et al., (1996)28 undertook a study comparing ropivaccaine 
and bupivacaine during combined sciaticofemoral nerve block and found that 
bupivacaine had a later onset of sensory and motor blockade but a comparable duration 
of analgesia. 
 Andrea Casati et al., (1997)29 in their study compared 0.5% bupivacaine with 
0.5% ropivacaine for sciatic nerve block for Hallux valgus surgery. They concluded that 
20ml of 0.5% ropivacaine and 0.5% bupivacaine produced comparable surgical block 
with prolonged post operative analgesia. There was no difference in the time of recovery 
of motor and sensory function and duration of post operative analgesia. 
 Mc Glade - DP, Kalpokas HV, Mooney P.H, Buckland MP et al., (1997)30 in 
their study compared 0.5% bupivacaine and 0.5% ropivacaine in patients undergoing 
lower limb orthopaedic surgery. They compared onset time, duration of spread of sensory 
block, duration and degree of motor blockade and hemodynamic changes. The onset and 
duration of analgesia at T10 dermatome was 10 mins and 3.5 hours for ropivacaine and 10 
minutes and 3.4 hours for bupivacaine respectively. Maximum epidural block height was 
T6 for both drugs. The incidence of complete motor block was low in both groups and 
cardio vascular changes were similar in both groups. 
 Casati A, Borghi B, Fanelli G, Santorsola R et al., (2002)31 compared 0.5% 
levobupivacaine and 0.5% ropivacaine for sciatic nerve block for Hallux valgus repair. 
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Mean onset time of surgical block at sciatic nerve distribution was 30 minutes with 
levobupivacaine and 15 minutes with ropivacaine. No differences in the time to recovery 
of sensory and motor function were observed between the two groups whereas mean 
duration of analgesia was 16 hours for both levobupivacaine and 0.5% ropivacaine. They 
concluded that 20ml of either 0.5% levobupivacaine (or) 0.5%) ropivacaine provide 
comparable surgical block with prolonged postoperative analgesia. 
 Santorsola R, Casatic A, Moizo E, Fanelli G et al., (2001)32 compared the 
clinical profile of sciatic nerve block performed with either 0.5% levobupivacaine, 0.5% 
bupivacaine or 0.5% ropivacaine. Onset time of sciatic nerve block was 15 minutes with 
levobupivacaine, 30 minutes with bupivacaine and 15 minutes with ropivacaine. No 
differences in the quality of nerve block as well as in the nerve block resolution times 
were observed among the three groups. Duration of post operative analgesia was 16 
hours (8-24) with levobupivacaine, 14 (8-24) hours with bupivacaine and 17 hours with 
ropivacaine. They concluded that 0.5% levobupivacaine for sciatic nerve block results in 
similar clinical effects as those produced by using the same volume and concentration of 
either bupivacaine and ropivacaine. 
 Morrison LM, Emanuelson BM et al., (1994)33 did a study on the efficacy and 
kinetics of extradural ropivacaine compared with bupivacaine. They found no difference 
in frequency, onset, duration or spread of sensory block. However, motor block was less 
intense and of shorter duration with ropivacaine than bupivacaine cardiovascular changes 
were similar. The peak plasma concentration of ropivacaine was significantly greater and 
the T life significantly shorter. The systemic kinetics of ropivacaine were not 
influenced significantly by varying the concentration or volume administered. 
 Bader AM, Datta 5, Flanagan H, Covino BG. et al., (1989)34 compared the in 
vitro potency, onset and recovery from block of ropivacaine and bupivacaine using an 
isolated rabbit vagus nerve. The effect of varying concentrations of ropivacaine on the 
compound action potential of A and C more fibres was assessed, to determine whether 
motor and sensory fibres have different senstivities to the two agents. The results showed 
that the depressent effect of bupivacaine was 16% greater than that of ropivacaine on 
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motor fibres, but only 3% greater on sensory fibres. Thus at the concentrations tested, 
ropivacaine appears to produce relatively less blockade on motor fibres than does 
bupivacaine but with similar sensory blockade. 
 Bertini L et al., (1999)35 conducted a study comparing 0.5% ropivacaine and 
0.5% bupivacaine for axillary plexus block. They demonstrated that the duration of 
motor block with bupivacaine was significantly longer than that of ropivacaine. 
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 MATERIALS AND METHODS 
 This study was carried out in orthopaedic theater, Government General Hospital, 
Chennai after obtaining hospital ethical committee approval. The aim of the study was to 
compare the efficacy of an equal volume of two local anaesthetics, 0.5% Bupivacaine 
and 0.5% Ropivacaine in combined femoral nerve block and sciatic nerve block (anterior 
approach). 
SELECTION OF CASES 
 40 Patients in the age group of 18-60 years belonging to ASA I and ASA II who 
were to undergo elective lower limb knee and below knee orthopaedic surgery were 
chosen. All the patients were assessed and those with normal clinical, biochemical, 
radiological and hematological parameters were selected. Informed written consent was 
obtained from all the patients. All the patients were randomly allocated in to two groups. 
Group B and Group R, containing 20 patients in each group. 
STUDY DESIGN 
 The study was done in a randomized double blind fashion, patients were 
allocated to one of the two groups in a prospective randomized, double blinded study 
design Group B (n=20) received 0.5% bupivacaine with adrenaline (1:400000) and 
Group R received 0.5% ropivacaine with adrenaline (1:400000). The syringes containing 
the local anaesthetic solution were prepared in a double blinded fashion by one of the 
anaesthesiologist, who was not involved in further patient evaluation. 
 Group B - Received 0.5% Bupivacaine with adrenaline (1:400000) 
15 ml for femoral nerve block and      20 ml for sciatic 
nerve block. 
 Group R - Received 0.5% Ropivacaine with adrenaline (1:400000) 
15 ml for femoral nerve block and      20 ml for sciatic 
nerve block. 
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INCLUSION CRITERIA 
 Assessed patients of ASA physical status I & II. 
 Normal biochemical and hematological parameters. 
 Age group between 18-60 years. 
 No known neurological deficit. 
 No local sepsis 
 Informed written consent 
 Weight of the patient  70 kg (because 35 ml of local anaesthetic solution was 
used for blocking the nerves). 
EXCLUSION CRITERIA 
 Technical failure 
 Patient not willing 
 Neurological disorders/deformity of spine 
 History of allergy to local anaesthetics 
 Bleeding diathesis. 
MATERIALS 
 Materials include IV set up for infusion and resuscitation equipments including. 
 Intubation set 
 Ventilation / oxygenation equipment 
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 Atropine, Sedative (diazepam) 
 Thiopentone sodium 
 Succinyl choline 
 Vasopressor : Ephedrine 
 Adrenaline 
 Local anaesthetics 
 - 0.5% Bupivacaine with adrenaline (1:4,00,000) 
 - 0.5% Ropivacaine with adrenaline (1:4,00,000) 
EQUIPMENTS 
 Caliper to measure sub scapular skin fold thickness. 
 Measuring tape for mid arm circumference, calf circumference, knee. 
  Height for estimating weight of non-ambulatory patients. 
 Prep. solution, sterile gloves 
 Drape 
 Patch electrode, Marker pen 
 Nerve stimulator (Fischer & Paykel) capable of delivering single twitch at 1HZ 
with a current strength between 0.2 to 5 mA 
 Blunt tipped insulated nerve stimulating needle (Braun) with extension tubing for 
drug administration. 
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METHODS 
 Preoperative preparation 
 Patients were assessed preoperatively, procedure was explained to the patient and 
informed written consent was obtained. They were assessed with particular 
attention for any contraindications. Exact weight was recorded. In bed-ridden 
patients, approximate weight calculated from these values -knee height (KH), 
mid arm circumference (MAC), calf circumferences (CC) and subscapular skin 
fold thickness (SSF) 
Weight (women) = (1.27 x CC) + (0.87 x KH ) + 
   (0.98 x MAC) + (0.4 x SSF) - 62.35 
 
Weight (men) = (0.98 x CC) + (1.16 X KH) + (1.73 X MAC) 
    + (0.37 x SSF) - 81 
Overnight fasting was advised 
 Assessment of pain using verbal rating scale-VRS (intra operatively) and visual 
analogue scale-VAS (post operatively) was explained to the patient pre-operatively. 
Pre Medication 
 All the patients were premedicated orally with Tab. Diazepam 10mg 2 hrs before 
surgery. 
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CONDUCT OF ANAESTHESIA 
 On arrival of the patient in the operating room, ECG, Pulse oximetry and blood 
pressure base line values were recorded. After explaining the procedure to the patient an 
intravenous access was obtained in the dorsum of the hand and intravenous infusion of 
Ringer Lactate was started. Injection midazolam 2 mg I.V was given for all patients. The 
patients were administered femoral nerve block and sciatic nerve block by anterior 
approach as follows: 
FEMORAL NERVE BLOCK 
Positioning 
 Patient was positioned supine with thigh abducted 15 on a flat surface. The 
inguinal region and thigh was carefully and thoroughly cleaned with povidone iodine 
solution and sterile drapes were placed around the site. 
Land marks 
 Three essential land marks, the anterior superior iliac spine, pubic tubercle and 
femoral artery were identified. 
a. Inguinal ligament: Line drawn between the anterior superior iliac spine and pubic 
tubercle. 
b. Femoral artery just below the inguinal ligament. 
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Procedure 
 Conductive patches were attached on the ipsilateral thoracic wall and connected 
to the nerve stimulator. 
 The site of puncture for entry in to the perineural space of the femoral nerve is 
located approximately 1.5 cm below the inguinal ligament and 1.5 cm lateral to the 
femoral artery. A 2 inch 22 gauge short bevelled teflon - coated nerve stimulater needle 
with stimulator attached is advanced slowly at an angle of 45 to skin, parallel to the 
femoral artery in a craniodorsal direction. Once the needle is through the skin the nerve 
stimulation output is adjusted to 1-2 mA with a frequency of 1.0 HZ. 
 A motar evoked response of movement of patella indicates stimulation of femoral 
nerve. Once the nerve is located the needle position optimized and the stimulus intensity 
is adjusted downward until a patellar twitch remains present at a output of 0.2 to 0.4 mA. 
Through the extension tubing after negative aspiration, 15 ml of local anaesthetic 
solution was administered. 
SCIATIC NERVE BLOCK BY ANTERIOR APPROACH OF BECK 
Positioning 
 Patient was positioned supine, legs extended with slight internal rotation. 
Land Marks 
 Anterior superior iliac spine, pubic tubercle, greater trochanter, lesser trochanter 
were identified. 
Procedure 
 After orientation of the landmarks, a line was drawn between the anterior 
superior iliac spine and pubic tubercle. The line was divided into medial, middle and 
lateral thirds. From the junction of the medial and middle thirds, a line is drawn at a right 
angles caudally. A second line was drawn parallel to the first from the upper tip of the 
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greater trochanter across the thigh. The intersection of this line with the right angle line 
from the first line is marked. This point is the point of insertion of the needle for the 
anterior sciatic block. A 15 cm 20 G short bevel insulated nerve stimulating needle with 
extension tubing for drug administration is introduced at right angles to the skin through 
a skin wheal and was advanced in the direction of the shaft of femur. After bony contact, 
the needle was withdrawn slightly and redirected medially and advanced beyond the 
shaft of femur. At this point, the sciatic nerve is adjacent to the lesser trochanter. Nerve 
stimulator was attached. Stimulation frequency was set at 1 HZ. The intensity of the 
stimulating current was initially set at 1-2 mA to elicit dorsiflexion on plantar flexion of 
the foot. After negative aspiration, 20 ml of local anaesthetic was injected. 
Evaluation of the Block 
 The following observations were made: 
1. Immediately following nerve blockade patients were evaluated every minute for 
first 20 minutes then every 5 minutes thereafter for sensory and motor blockade 
by a clinician unaware of the identity of the injected solution. 
2. Time of the onset of sensory blockade was noted by testing for pinprick sensation 
using 26 gauge hollow needle over the area of supply of femoral and sciatic nerve 
seperatively and it is taken as the onset time for sensory blockade for that 
particular nerve. 
3. The degree of motor blockade was assessed upon Bromage scale. 
 0 - no motor paralysis 
 1 - inability to raise extended leg 
 2 - inability to flex the knee 
 3 - loss of ankle dorsiflexion 
  In our study motor blockade was assessed based on orthopaedic problem. For eg. 
 
 
 
52 
Loss of ankle dorsiflexion was assessed for problems such as fracture patella etc, and 
inability to flex the knee was assessed for problems in the foot. 
4. The degree of pain during surgery was assessed with a 3 point verbal rating scale 
score  (VRS) 
 VRS: 0 - no pain 
  1 - pain 
  2 - unbearable pain 
 If VRS  1 patient received supplemental analgesia and were excluded from the 
study. 
 The quality of combined femoral nerve block and sciatic nerve block was 
evaluated as follows, according to the need for supplementary IV analgesia. 
Satisfactory nerve block  - No analgesia required to complete the 
surgery. 
Unsatisfactory nerve block - Supplemental IV analgesia required to complete 
the surgery. 
Failed nerve block   - General anaesthesia required to complete 
the surgery. 
 Patients with unsatisfactory nerve block and failed nerve blocks were excluded 
from the study. 
5. Vital signs monitoring using non invasive blood pressure, heart rate measured at 
0,5,10,15 min and every 15 mins thereafter till one hr. 30 min and every 30 mins 
thereafter throughout the intraoperative procedure. ECG and SPO2 monitored 
continuously. Time O for clinical assessments was the completion of anaesthetic 
injection at the sciatic nerve. 
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6. Local anaesthetic toxic reactions including subjective and objective 
manifestations like circumoral numbness, tinnitus, twitching, convulsion etc., if 
any were looked for and appropriate measures were planned. 
7. Hemodynamic changes requiring anaesthesiologist's intervention (increased 
intravenous fluids, blood, inotropes) were looked after. 
8. Duration of sensory analgesia was tested post operatively every 15 minutes using 
the VAS score. 
9. Motor blockade was assessed every 30 minutes after the onset of motor blockade. 
Duration of motor blockade was taken as the time interval from the onset to the 
resolution of motor block. 
10. Any other complications like nerve injury, hematoma or vascular injury were 
looked for. 
PARAMETERS STUDIED 
1. Onset of sensory analgesia 
 This is the time in minutes from the injection of the drug to the lack of 
appreciation of pinprick sensation. 
2. Onset of motor blockade 
 This is the time in minutes from the time of drug injection to the loss of ankle 
dorsiflexion for orthopaedic problems such as fracture patella, fracture both bones leg, 
etc. (or) from the time of drug injection to inability to flex the knee for orthopaedic 
problems in the foot. 
3. Duration of sensory analgesia 
 The duration of sensory analgesia is the time in minutes from the onset of 
analgesia to the time administration of rescue analgesia. Rescue analgesia was provided 
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with 30 mg of pentazocine intramuscularly when the VAS  4. 
4. Duration of motor blockade 
 This is the time from the onset of motor blockade to the recovery of motor block. 
 All the patients included in the study were monitored postoperatively for a period 
of 12 hours. 
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 OBSERVATIONS AND RESULTS 
 The patients included in the study were divided into two groups consisting of 18 
patients each. 
 Group B (n = 18) received 0.5% bupivacaine 
 
 Group R (n = 18) received 0.5% ropivacaine 
 
 TABLE 1 : DISTRIBUTION OF AGE 
 
Age in years Group Total 
 Bupivacaine Ropivacaine  
 Number Percent Number Percent  
< 30 1 5.6 3 16.6 4 
31-40 7 38.9 7 38.9 14 
41-50 7 38.9 5 27.9 12 
> 50 3 16.6 3 16.6 6 
Total 18 100 18 100 36 
Mean 41.72 40.44 t= 0.45 
p= 0.67 
SD 8.288 9.269  
 
  
 The two groups were similar with respect to age, the difference was not 
statistically significant. 
 TABLE 2: DISTRIBUTION OF WEIGHT 
 
Weight in 
Kgs 
Group Total 
 Bupivacaine Ropivacaine  
 Number Percent Number Percent  
70-75 12 66.7 12 66.7 24 
75-80 4 22.2 5 27.7 9 
80-85 2 11.1 1 5.6 3 
Total 18 100 18 100 36 
Mean 74.94 74.78 t= 0.15 
p= 0.89 
SD 3.244 3.507  
 
 
 There was no statistically significant difference between the two groups as 
regards weight distribution. 
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 TABLE 3: DISTRIBUTION OF BASAL HEART RATE 
Heart rate Group  
Total 
 Bupivacaine Ropivacaine  
 Number Percent Number Percent  
70-75 4 22.2 6 33.3 10 
76-80 7 38.9 4 22.2 11 
81-85 5 27.8 6 33.3 11 
86-90 2 11.1 2 11.1 4 
Total 18 100 18 100 36 
Mean 79.61 79.22 t= 0.24 
p= 0.80 
SD 4.258 5.242  
 
 
 There was no statistically significant difference between the two groups as 
regards basal heart rate. 
 
 TABLE 4: BASAL MEAN ARTERIAL PRESSURE (MAP) 
 
MAP Group Total 
 Bupivacaine Ropivacaine  
 Number Percent Number Percent  
90-95 10 55.5 11 61.1 21 
96-100 4 22.2 5 27.8 9 
101-105 4 22.2 2 11.1 6 
Total 18 100 18 100 36 
Mean 96.17 95.39 t= 0.53 
p= 0.59 
SD 4.706 3.987  
 
 
 There was no statistically significant difference between the two groups as 
regards basal mean arterial pressure. 
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 TABLE 5 : DISTRIBUTION OF DURATION OF SURGERY (DOS) 
 
DOS in 
mins 
Group Total 
 Bupivacaine Ropivacaine  
 Number Percent Number Percent  
50-70 11 61.1 11 61.1 22 
70-90 6 33.3 5 27.8 11 
90-110 1 5.6 2 11.1 3 
Total 18 100 18 100 36 
Mean 70.00 69.39 t= 0.16 
p= 0.87 
SD 11.412 11.521  
 
 
 There was no statistically significant difference in duration surgery between the  
two groups. 
 
 TABLE 6 : DISTRIBUTION OF ONSET OF MOTOR BLOCK (OOMB) 
 
OOMB in 
mins 
Group Total 
 Bupivacaine Ropivacaine  
 Number Percent Number Percent  
18-20 5 27.8 5 27.8 10 
20-22 9 50.0 6 33.3 15 
22-24 4 22.2 6 33.3 10 
24-26 - - 1 5.6 1 
Total 18 100  100 36 
Mean 21.28 21.64 t= 0.64 
p= 0.53 
SD 1.574 1.805  
 
 
 There was no statistically significant difference in onset of motor blockade 
between the two groups. 
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 TABLE 7 : DISTRIBUTION OF ONSET OF SENSORY BLOCKADE  
 
 FOR FEMORAL NERVE 
 
Group N Mean (mins) SD t-test 
Bupivacaine 18 13.39 1.33 t = 0.88 
p = 0.39 
Ropivacaine 18 13.69 0.62  
  
 
 TABLE 8 : DISTRIBUTION OF ONSET OF SENSORY BLOCKADE 
  FOR SCIATIC NERVE 
Group N Mean (mins) SD t-test 
Bupivacaine 18 17.19 1.29 t = 0.13 
p = 0.89 
Ropivacaine 18 17.14 1.23  
 
 The time of onset of sensory blockade was not statistically significant between 
the two groups. 
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 TABLE 9: HEART RATE DURING SURGERY 
 
Heart Rate Group 
 Bupivacaine Ropivacaine 
 Mean SD Mean SD 
0 mins 86.28 6.04 84.11 6.42 
5 mins 85.44 5.56 83.61 6.15 
10 mins 84.72 7.13 82.78 6.27 
15 mins 84.67 5.89 83.17 5.63 
30 mins 85.50 5.87 84.22 7.18 
45 mins 86.33 6.23 83.61 5.74 
60 mins 85.11 6.30 84.44 6.19 
75 mins 85.44 5.80 83.17 6.71 
90 mins 85.17 4.66 85.11 6.32 
105 mins 85.17 4.06 84.61 6.55 
120 mins 85.56 4.94 84.44 5.41 
150 mins 85.89 5.26 84.78 6.43 
180 mins 84.56 7.23 83.22 5.99 
 
 
 STATISTICAL ANALYSIS OF HEART RATE 
 
Heart rate Sum of 
squares 
Df Mean 
Square 
F P value 
Within group 122.63 12 10.22 0.32 0.99 
Between group 238.36 1 238.36 2.68 0.11 
 
 There was no statistically significant difference in the observed heart rate during 
surgery between the two groups. 
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 TABLE 10 : MAP DURING SURGERY 
 
MAP Group 
 Bupivacaine Ropivacaine 
 Mean SD Mean SD 
0 mins 98.67 5.83 97.89 6.12 
5 mins 96.39 7.44 95.94 6.59 
10 mins 95.89 4.81 94.44 7.07 
15 mins 95.89 5.96 94.33 6.52 
30 mins 98.00 5.52 96.61 6.25 
45 mins 98.22 5.31 97.44 5.87 
60 mins 98.94 4.22 98.83 5.74 
75 mins 99.78 5.00 98.61 5.95 
90 mins 97.72 4.99 98.28 5.57 
105 mins 98.67 4.95 98.44 5.52 
120 mins 99.11 4.52 99.44 5.49 
150 mins 97.89 6.43 97.94 5.08 
180 mins 96.06 5.99 94.78 6.80 
 
 
 STATISTICAL ANALYSIS OF MAP 
MAP Sum of 
Squares 
Df Mean 
Square 
F p value 
Within group 990.36 12 82.53 0.88 0.28 
Between group 46.80 1 46.80 0.49 0.48 
 
 There was no statistically significant difference in the observed mean arterial 
pressure during surgery between the two groups. 
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 TABLE 11 : DISTRIBUTION OF DURATION OF SENSORY 
 ANALGESIA (DOSA) 
 
DOSA in 
mins 
Group Total 
 Bupivacaine Ropivacaine  
 Number Percent Number Percent  
880-900 3 16.7 2 11.1 5 
900-920 2 11.1 6 33.3 8 
920-940 6 33.3 4 22.2 10 
940-960 7 38.9 6 33.3 13 
Total 18 100 18 100 36 
Mean 933.67 924.22 t= 1.34 
p= 0.19 
SD 21.774 20.587  
 
 
 Thus there was no statistically significant difference in the duration of sensory 
analgesia between the two groups. 
 TABLE 12 : DISTRIBUTION OF DURATION OF MOTOR  
 BLOCK (DOMB) 
 
DOMB in 
mins 
Group Total 
 Bupivacaine Ropivacaine  
 Number Percent Number Percent  
175-200 - - 16 88.9 16 
200-225 - - 2 11.1 2 
225-250 15 83.3 - - 15 
250-275 3 16.7 - - 3 
Total 18 100 18 100 36 
Mean 243.78 189.11 t= 16.86 
p = 0.001 
SD 9.564 9.887  
 
P<0.05 Significant 
P<0.01 Highly significant 
 There was statistically significant difference in the duration of motor blockade 
between the two groups. The duration of motor blockade with bupivacaine was 
significantly longer than that produced by ropivacine. 
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 DISCUSSION 
 Orthopaedic surgical procedure involve significant physical and emotional stress 
to the patients. Regional analgesia, commonly in the form of subarachnoid block or 
epidural analgesia have been the main stay of orthopaedic anaesthesia for lower limb 
orthopaedic surgeries. However, the central neuraxial anaesthesia is associated with 
iatrogenic complications like hypotension and urinary retention. It cannot be performed 
in cardiovascularly unstable patients and requires change in position of the patient and 
also requires change in position of the patients (Sitting or lying to one side) for 
administration of central neuraxial blockade, which is painful and uncomfortable to the 
patient who has lower limb orthopaedic problem. 
 Surgical anaesthesia of lower limb knee and below knee orthopaedic surgeries by 
combined femoral nerve block and sciatic nerve block. (anterior approach) seems to be 
an attractive option. 
 In out study, combined femoral nerve block and sciatic nerve block (anterior 
approach) was chosen based on the following studies. 
 Winnie AP et al.,14 Anker - Moller E et al.,15 performed 3-in-1 block by single 
injection of local anaesthetic into the fascial envelope of femoral nerve. 
 Sansone Y, Deponti A et al.,16 performed combined sciatic and femoral nerve 
block for knee arthroscopy. The results were good in 87%, adequate in 12% and poor in 
1%. The technique proved adequate for knee arthroscopic surgery, reproducibility was 
excellent, costs and hospital stays were reduced with respect to general anaesthesia, and 
surgeon and patient satisfaction was high. 
 Manani G, Angel et al.,17 compared sciatic nerve block by anterior  and posterior 
approach for operations on lower extremity. Sciatic nerve block by anterior approach 
granted a more prolonged analgesia. This technique was suitable for trauma patients 
immobilized in supine position, for patients with skeletal traction on Zupinger frame, 
both for surgery and for closed reduction of lower extremity procedures. 
 Luber MJ, Greengrass R et al.,20 studied the patient satisfaction and efffectivess 
of combined femoral sciatic nerve block for total knee arthroscopy. It appeared to have 
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advantages for early postoperative analgesia , leading to increased patient comfort and 
satisfaction. 
 Allen JG, Denny NM et al.,21 carried out a study comparing spinal anaesthesia 
and combined sciatic femoral 3-in-1 block for postoperative analgesia following total 
knee arthroplasty. They reported that, in comparison with spinal anaesthesia, 
sciaticofemoral block resulted in superior analgesia, reduced morphine consumptions for 
first 24 hours. 
 Marhofer P, Schrogendorferk et al.,23 studied combined sciatic nerve and 3-in-1 
block in high risk patients. They concluded that this technique is a safe method for 
surgery in lower limb particularly in hemodynamically unstable patients. 
 
 Pham - Dang C, Beaumont S et al.,24 reported a case of Acute toxic accident 
following lumbar plexus block with bupivacaine. The patient experienced ventricular 
dysrythmias and seizures. Patient was resuscitated and stable hemodynamic conditions 
were restored after 1 hour. 
 Mc Clure JH25 in his review article on ropivocaine has stated a fovourable 
cardiotoxic profile of ropivacaine compared with bupivacaine Bupivacaine produced 
more severe arrhythmias than those observed with ropivacaine. The development of ECG 
disturbances and severe myocardial depression was more rapid with bupivacaine than 
ropivacaine. 
 In our study, we compared 0.5% bupivacaine and 0.5% ropivacaine to determine 
the optimal long acting anaesthetic for combined femoral nerve block and sciatic nerve 
block because of the potentially improved safety profile of ropivacaine. 
 Patients were divided into two groups, group B and R containing 20 patients in 
each group, finally only 18 patients in each group were included for statistical analysis. 
In group B there was 1 block failure and 1 patient required supplemental analgesia. In 
group R 2 patients required supplemental analgesia. 
 Patients in both groups did not differ with respect to age distribution, sex 
distribution, ASA physical status, weight distribution or duration of surgery. 
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Onset of sensory analgesia 
 The onset of sensory analgesia was tested by the loss of pinprick sensation in area 
of supply of femoral and sciatic nerve. In our study, the time of onset of sensory 
analgesia was between 13 and 17 mins in both groups. The time of onset of sensory 
analgesia was not statistically significant between the two groups. These findings were 
consistent with the findings observed by Greengrass RA, Klein SM et al., 26 who 
observed that the mean onset time of sensory analgesia was between 14 and 18 minutes 
in both groups. 
 Marhofer P et al.,27  demonstrated similar onset of analgesia between the 
bupivacaine and ropivacaine. Out study showed similar onset time of analgesia between 
the two groups. This correlates with the study conducted by Andrea casati et al.,29 
Onset of motor blockade 
 The onset of motor blockade was assessed by bromage scale based on orthopedic 
problem. In our study, the time of onset of motor blockade was found to the 21.281.57 
minutes for bupivacaine group and 21.64  1.80 minutes for ropivacaine group. The 
difference was not statistically significant. These finding correlates with the findings 
made by Greengrass RA, Klein SM et al.,26 
 The onset time for motor blockade was similar between the two groups in our 
study. This is consistent with the studies of Andrea casati29, Mc Glade DP, Buckland MR 
et al.,30 
Duration of Sensory analgesia 
 The duration of sensory analgesia was 933.6721.77 minutes for group B and 
924.2220.58 minutes for group R. There was no statistically significant difference in the 
duration of analgesia between the two groups. 
 The duration of sensory analgesia was found to be similar between bupivacaine 
and ropivacaine in the study conducted by Beccaria P et al.,28 Andrea casati et al.,29,31 Mc 
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Glade DP et al.,30 Faneli G et al.,31 Sanstorsola et al.,31,32 also demonstrated comparable 
duration of sensory analgesia between bupivacaine and ropivacaine. In our study also, the 
duration of sensory analgesia was comparable between the two groups. 
Duration of motor blockade 
 The duration of motor blockade in our study wasd 243.789.56 minutes for group 
B and 189.119.88 minutes for group R. The difference between the two groups was 
statistically highly significant. 
 These findings correlate with the findings made by Greengrass RA et al.,26 Mc 
Glade DP et al.,30 Bertini et al.,35. 
 Bader et al.,34 showed that the depressant effect of bupivacaine was 16% greater 
than that of ropivacaine on motor fibres and that it was statistically significant. 
 These findings correlate with the findings in our study which showed a lesser 
duration of motor blockade with ropivacaine when compared to bupivacaine. 
Hemodynamics 
 In our study, no significant difference was observed with respect to heart rate and 
mean arterial pressure. This finding is consistent with Allen JG, Denny NM et al.,21 
Marhofer P et al.,23 Mc Glade DP et al.,30 Morrison LM33 who concluded that there was 
no significant hemodynamic changes after administration of the block with bupivacaine 
and ropivaccaine. 
 Considering the literature regarding the cardiovascular and central nervous 
system toxicity of ropivaccaine and bupivacaine, ropivacaine seems to be less toxic than 
bupivacaine. Another possible mechanism for the lower toxicity of ropivacaine compared 
with bupivacaine could be an intrinsic vasoconstrictive activity of ropivacaine with 
subsequent slow plasma uptake. These are potential clinical advantages during neural 
blockade when large volumes of local anaesthetic are required for peripheral nerve 
blocks in cardiovasularly compromised patients and in those cases of inadvertent 
intravascular administration of local anaesthetic during peripheral nerve blockade. 
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SUMMARY 
 On comparing 0.5% bupivacaine with 0.5% ropivacaine for combined femoral 
nerve block and sciatic nerve block (Anterior approach), it was noted  
  Onset of sensory analgesia was comparable between the two groups. 
  Onset of motor blockade was similar with bupivacaine and ropivacaine. 
  Duration of sensory analgesia was similar with both drugs 
  Motor blockade was of significantly lesser duration with ropivacaine 
compared to bupivacaine. 
  Both drugs did not produce significant changes in the hemodynamic 
parameters. 
  The lower intrinsic toxicity of ropivacaine and its improved safety profile 
offers it an advantage over bupivacaine for combined femoral nerve block 
and sciatic nerve block (Anterior approach). 
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 CONCLUSION 
 In conclusion, the technique of combined femoral and sciatic nerve block by 
anterior approach is a safe and reliable alternative to more common forms of anaesthesia 
for surgeries in the knee and below knee.  
 From this study it can be inferred that 0.5% Ropivacaine has a comparable 
sensory blockade, lesser duration of motor blockade and an increased safety margin over 
0.5% Bupivacaine in combined femoral nerve block and sciatic nerve block. 
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 PROTOCOL 
TOPIC 
 Comparison of 0.5% Bupivacaine and 0.5% Ropivacaine for combined femoral 
nerve block and sciatic nerve block (anterior approach). 
OBJECTIVE 
 To compare the onset time, duration of sensory analgesia and motor blockade, the 
hemodynamic changes and also to evaluate the efficacy and safety of 0.5% Bupivacaine 
with 0.5% Ropivacaine for combined femoral nerve block and sciatic nerve block 
(anterior approach) in patients undergoing lower limb knee and below knee orthopaedic 
procedures. 
PROCEDURE 
Type of Patient : ASA I/II 
Age    : 18-60 years 
Type of Surgery  : Lower Limb knee and below knee orthopaedic 
procedures 
Anaesthesia  : Combined femoral nerve block and sciatic nerve block 
(anterior approach) 
Premedication  : Tab. Diazepam 10mg 2 hours before surgery. 
 
 
 
 
 
Combined femoral nerve block and sciatic nerve block (anterior approach) 
 Group B Group R 
Femoral Nerve Block 15 ml 15 ml 
Sciatic Nerve Block 20 ml 20 ml 
 
IV Fluds   : Ringer lactate, Normal saline 
Monitors   : ECG, SPO2, NIBP. 
Parameters Observed 
  Onset of sensory analgesia 
  Onset of motor blockade 
  Duration of sensory analgesia 
  Duration of Motor blockade 
Exclusion criteria 
  Technical failure 
  Weight less than 70 kg. 
  Patient not willing 
  Local sepsis 
 
  History of allergy to local anaesthetics 
  Neurological disorders 
  Bleeding diathesis. 
 
 
 
 
 
 
Group B - Bupivacaine 
          
Onset of 
 Sensory Blockade S.No Age Sex Weight Duration of Surgery Femoral 
nerve Sciatic nerve 
Onset of  
Motor 
Blockade 
Duration Of 
Sensory 
Blockade 
Duration Of 
Motor  
Blockade 
1 31 M 75 74 14 19 22 938 240 
2 42 F 71 65 15 20.5 21 895 230 
3 38 M 72 90 13 16.5 19 960 230 
4 42 M 73 75 13.5 18 22 918 255 
5 49 F 72 65 12.5 17 18 892 235 
6 42 M 72 78 13 14.5 20 940 255 
7 53 F 81 65 14 16 21.5 950 245 
8 36 M 78 84 16 18.5 20.5 960 250 
9 28 M 78 68 13.5 17 24 948 235 
10 55 F 76 50 13.5 16 19 938 235 
11 38 M 82 60 14 17 21 948 240 
12 40 M 75 74 14 16.5 23 917 250 
13 43 M 74 64 14 17 22 950 249 
14 33 M 72 70 11 18 24 935 250 
15 47 M 72 54 12 17 20 925 260 
16 45 M 75 65 12 17 21 952 250 
17 32 M 77 94 11 17 23 940 230 
18 57 M 74 65 15 17 22 900 249 
 
 
 
 
 
 
Group R - Ropivacaine 
Onset of  
Sensory Blockade S.No Age Sex Weight Duration of Surgery Femoral 
nerve Sciatic nerve 
Onset of  
Motor 
Blockade 
Duration Of 
Sensory 
Blockade 
Duration Of 
 Motor 
Blockade 
1 32 F 72 72 12.5 17 22 960 189 
2 50 M 73 64 14.5 19 21 905 180 
3 53 M 73 92 13.5 18 19 942 200 
4 35 M 72 64 13.5 15.5 19 909 185 
5 52 M 71 75 14 18 23 902 190 
6 40 M 70 76 14.5 15.5 23 930 185 
7 32 M 75 82 14 17 19 930 190 
8 36 M 78 68 13.5 17 20 945 185 
9 36 M 75 65 13.5 18 24.5 945 190 
10 29 F 74 60 13.5 18 20.5 942 200 
11 45 M 78 50 13 16 21 890 210 
12 27 M 78 74 15 17.5 24 925 175 
13 40 M 71 62 13 19 24 912 180 
14 43 M 80 70 13.5 16 23 928 205 
15 45 M 76 62 13.5 15.5 20 919 175 
16 47 M 83 65 13.5 16 21.5 950 190 
17 58 M 75 94 14.5 16.5 23 892 195 
18 28 M 72 54 13.5 19 22 910 180 
 
 
 
 
 
 
Basal Heart Rate and Mean Arterial Pressure of Bupivacaine 
   
S.No 
Basal Heart Rate                          
                                        
                                        
Basal Mean  Arterial Pressure 
1 84 101 
2 72 92 
3 81 93 
4 84 102 
5 82 94 
6 75 94 
7 80 104 
8 77 98 
9 82 99 
10 88 90 
11 79 90 
12 78 90 
13 79 94 
14 75 94 
15 78 95 
16 79 98 
17 74 105 
18 86 98 
 
 
 
 
 
 
Basal Heart Rate and Mean Arterial Pressure of Ropivacaine 
   
S.No Basal Heart Rate Basal Mean  Arterial Pressure 
1 80 95 
2 72 96 
3 81 93 
4 84 100 
5 75 94 
6 82 96 
7 75 98 
8 74 104 
9 85 95 
10 79 94 
11 82 90 
12 80 92 
13 72 90 
14 71 94 
15 88 99 
16 84 90 
17 76 102 
18 86 95 
 
 
 
 
 
 
Heart rate observed during various time points of surgury (Bupivacaine) 
              
S.No 0 Mins 5 Mins 10 Mins 15 Mins 30 Mins 45 Mins 60 Mins 75 Mins 90 Mins 105 Mins 120 Mins 150 Mins 180 Mins
1 88 85 98 80 86 88 88 83 80 86 85 88 98 
2 88 82 88 88 84 85 85 78 88 84 93 85 88 
3 86 82 78 84 86 82 82 96 84 86 82 82 78 
4 86 89 72 88 89 88 78 78 88 82 95 89 72 
5 90 79 76 89 75 85 72 86 89 84 79 80 76 
6 83 94 82 93 93 95 91 95 90 90 79 92 79 
7 87 89 88 88 83 80 80 85 88 83 82 80 88 
8 96 94 92 96 78 82 82 89 96 88 92 82 92 
9 78 92 94 78 96 92 92 88 80 90 90 92 94 
10 84 76 90 84 78 84 87 80 84 82 86 87 90 
11 89 83 73 83 86 72 85 80 83 79 83 83 73 
12 79 89 88 90 95 92 92 88 90 95 84 89 88 
13 92 84 80 79 85 89 89 92 79 85 80 89 80 
14 90 92 90 85 89 98 98 86 85 89 89 98 90 
15 70 86 84 72 88 78 78 84 82 82 87 78 84 
16 90 78 86 80 80 88 88 86 80 82 85 88 86 
17 85 80 84 87 80 87 80 89 87 80 89 80 84 
18 92 85 82 80 88 89 85 75 80 86 80 84 82 
 
 
 
 
 
 
Heart rate observed during various time points of surgery (Ropivacaine) 
              
              
S.No 0 Mins 5 Mins 10 Mins 15 Mins 30 Mins 45 Mins 60 Mins 75 Mins 90 Mins 105 Mins 120 Mins 150 Mins 180 Mins
1 72 84 78 78 80 84 93 93 80 92 85 93 78 
2 80 88 70 86 80 75 89 89 72 94 81 89 70 
3 89 88 88 82 84 86 78 86 89 92 80 78 88 
4 85 80 80 90 76 78 72 72 85 83 89 72 80 
5 74 75 78 98 90 84 82 82 94 82 80 82 78 
6 89 97 79 83 92 89 86 72 88 79 78 92 88 
7 86 78 84 85 98 85 85 85 78 85 89 85 84 
8 90 86 94 89 75 86 94 94 90 84 94 94 90 
9 76 74 74 80 74 88 90 90 76 75 92 90 74 
10 92 78 90 83 96 90 85 85 92 86 76 85 90 
11 97 87 89 82 79 98 74 74 97 78 83 74 89 
12 85 95 85 79 94 85 78 78 85 84 89 78 85 
13 79 86 88 75 80 75 82 82 86 75 84 82 88 
14 85 80 82 84 86 78 92 84 85 78 92 92 85 
15 84 82 86 75 82 80 84 75 84 86 86 84 86 
16 84 80 86 86 82 83 88 88 84 82 78 88 86 
17 87 83 84 78 82 82 85 85 87 90 80 85 84 
18 80 84 75 84 86 79 83 83 80 98 84 83 75 
 
 
 
 
 
 
Mean Arterial Pressure observed during various time points of surgery (Bupivacaine) 
              
S.No 0 Mins 5 Mins 10 Mins 15 Mins 30 Mins 45 Mins 60 Mins 75 Mins 90 Mins 105 Mins 120 Mins 150 Mins 180 Mins
1 94 98 97 95 97 97 97 92 105 97 102 95 98 
2 99 89 86 88 91 96 96 96 91 98 104 110 88 
3 110 109 102 93 105 89 98 102 106 95 103 93 104 
4 92 103 93 96 95 102 102 96 90 104 104 98 98 
5 108 95 103 92 101 94 105 97 99 92 102 98 94 
6 104 100 92 98 104 106 105 102 100 102 100 98 102 
7 102 89 91 89 91 103 103 102 98 103 95 89 92 
8 102 105 101 104 96 100 100 95 99 100 93 104 108 
9 95 87 98 108 91 104 104 105 97 106 95 108 92 
10 105 93 99 95 92 92 92 108 96 92 98 95 90 
11 95 108 92 106 96 98 102 94 97 98 106 106 105 
12 102 97 102 94 105 107 94 98 107 107 98 93 96 
13 98 85 89 91 89 95 95 98 92 95 91 91 87 
14 89 94 94 93 101 93 98 99 102 91 95 93 94 
15 91 85 94 95 101 94 99 101 98 96 98 102 90 
16 98 98 93 90 107 94 94 105 95 96 105 92 96 
17 94 98 101 94 99 99 94 98 95 99 96 92 95 
18 98 102 99 105 103 105 103 108 92 105 99 105 100 
 
 
 
 
 
 
Mean Arterial Pressure observed during various time points of surgery (Ropivacaine) 
              
S.No 0 Mins 5 Mins 10 Mins 15 Mins 30 Mins 45 Mins 60 Mins 75 Mins 90 Mins 105 Mins 120 Mins 150 Mins 180 Mins
1 92 96 95 94 95 99 99 91 102 99 99 98 93 
2 101 91 89 84 96 98 102 99 98 101 99 94 98 
3 108 107 87 89 98 87 97 98 94 108 104 105 102 
4 87 105 104 98 85 106 94 105 92 92 108 94 96 
5 110 95 92 89 102 92 94 96 89 110 93 95 84 
6 95 97 93 97 96 94 105 105 102 97 102 93 98 
7 104 90 93 87 92 105 105 92 98 103 105 94 94 
8 100 107 101 108 108 98 98 100 95 100 98 104 92 
9 97 99 96 106 102 106 97 108 102 97 100 99 90 
10 107 91 85 93 98 90 90 96 96 107 94 94 92 
11 95 104 105 101 97 99 109 110 98 95 102 101 107 
12 94 95 95 95 97 100 100 94 108 95 108 98 90 
13 96 87 87 89 87 92 92 96 95 92 92 93 85 
14 91 92 96 90 90 91 91 91 104 91 92 108 106 
15 95 92 96 98 92 97 106 97 99 95 91 107 94 
16 98 101 102 94 94 96 96 107 110 98 106 96 98 
17 96 86 80 88 107 97 97 95 92 96 98 92 85 
18 96 92 104 98 103 107 107 95 95 96 99 98 102 
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